TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01064518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: RT001 (Botulinum Toxin Type A Topical Gel, Dose A) applied topically at Baseline (Day 0) to the lateral canthal lines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Dose B)
Description: Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
Study: NCT02337075

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PATH program
Description: A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH program
Description: A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Mentor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Mentor
Study: NCT00468273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
Description: IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
Study: NCT04514705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise with treadmil and weight training station
Study: NCT02216539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Description: Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard post-operative pain management
Description: Post-operative pain management treatments as per usual protocols in the hospital

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-operative pain management
Description: Post-operative pain management treatments as per usual protocols in the hospital
Study: NCT04121182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-line training
Description: Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
Study: NCT00583388

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
Study: NCT04769531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Joint Mobilizations
Description: i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip joint Muscle strength training
Description: i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip joint Muscle strength training
Description: i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee strengthening and flexibility exercises
Description: i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knee strengthening and flexibility exercises
Description: i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: knee strengthening and flexibility exercises
Description: i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:
Study: NCT04821193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin antisepsis with 5% NaHCO3 water solution
Description: In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin antisepsis with 2% Chlorhexidine Gluconate solution
Description: In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
Study: NCT00610610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Description: Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same shape Placebo
Study: NCT04243031

Intervention type: DEVICE
Intervention: QFT Access
Description: Measure of Interferon Gamma
Study: NCT02964572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
Study: NCT03307720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin Releasing Hormone Agonists (GNRH-A)
Description: Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin Releasing Hormone Agonists (GNRH-A)
Description: Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin Releasing Hormone Agonists (GNRH-A)
Description: Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
Study: NCT00385866

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cancer screening and health education
Description: The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cancer screening and health education
Description: The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: facilitation of Services to improve cancer screening
Description: The intervention group will receive cancer education and faciliation of services in the form of patient navigation
Study: NCT02964572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
Study: NCT02186444

Intervention type: OTHER
Intervention: Personalized Health Information Navigator (PHIN)
Description: The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs.

Intervention type: OTHER
Intervention: NCI Information Booklets (IB)
Description: Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks.
Study: NCT00766779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic cell transplantation
Description: low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Transplant treatment approach for consolidation
Description: Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
Study: NCT01363934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
Study: NCT00418587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 800 IU oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2000 IU oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4000 IU oral daily
Study: NCT00870194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide and sitagliptin
Description: exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
Study: NCT01886144

Intervention type: DEVICE
Intervention: Knee OA Brace
Study: NCT00870194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exenatide and placebo
Description: exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
Study: NCT04031872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Combination treatment with LY3200882 and capecitabine
Study: NCT01986972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing With Dentifrice
Description: The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothbrushing Without Dentifrice
Description: The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
Study: NCT03946865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki Therapy
Description: Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
Study: NCT03600454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia and epidural analgesia
Description: The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
Study: NCT03494218

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nociception Coma Scale (NCS)
Description: Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nociception Coma Scale (NCS)
Description: Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
Study: NCT02714270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified partograph

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paperless partograph
Study: NCT02102152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Study: NCT00005632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1-KLH vaccine/QS21
Study: NCT03239847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EndoPhys Sheath and Radial Arterial Line

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EndoPhys Sheath
Study: NCT02004015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of placebo
Description: 0.5 mg/kg milligram(s)/kilogram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of NMBA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of NMBA
Study: NCT01679509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic adnexal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-port laparoscopic adnexal surgery
Study: NCT03912545

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT02502513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief computerized intervention
Description: Computer game Tetris
Study: NCT00764907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV during reinduction
Study: NCT00764907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV during reinduction
Study: NCT02506829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling (Quitline)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling (Quitline)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
Study: NCT03307720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
Study: NCT01002469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium [1-13C] acetate
Study: NCT00304564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: subjects listen to music
Study: NCT02532647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02506829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Study: NCT00736632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill orally daily Calcium carbonate 500 mg twice daily
Study: NCT01754233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser for epidermal and dermal pigmented lesions
Study: NCT04216654

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA (enzyme-linked immunosorbent assay)
Description: ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA (enzyme-linked immunosorbent assay)
Description: ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA (enzyme-linked immunosorbent assay)
Description: ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
Study: NCT02087475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Local radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local radiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R0 resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R0 resection
Study: NCT02065960

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Study: NCT03185728

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iLook Out for Child Abuse
Description: Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iLook Out for Child Abuse
Description: Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting.
Study: NCT00822458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT01828047

Intervention type: DEVICE
Intervention: orthogonal polarization spectral (OPS) imaging
Description: orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces